Search Results
Your search for The ASCO Post matches 17419 pages
Showing 13851 - 13900Who Should Receive First-line BEACOPP Therapy for Hodgkin Lymphoma?
At the Pan Pacific Lymphoma Conference, held this year in Maui, Hawaii, Andreas Engert, MD, Chairman of the German Hodgkin Study Group, University Hospital of Cologne, Germany, led off the Hodgkin lymphoma section of the conference with a presentation on optimizing the use of BEACOPP (bleomycin,...
Updated Results from T-DM1 and Regorafenib Trials, plus Other Highlights from ESMO 2012
The 35th European Society for Medical Oncology (ESMO) Congress in Vienna broke all records for attendance, with about 16,000 attendees from all over the world. Some sessions were standing room only, including the Presidential Symposia, the ESMO-ASCO Joint Symposium on genomics in breast cancer, and ...
Introduction
This supplement to The ASCO Post highlights the proceedings of a satellite symposium that was presented as a case-based roundtable discussion titled, Monitoring, Treatment Resistance, and Treatment Failure in Chronic Myeloid Leukemia: Breaking Barriers to Improved Outcomes and Looking Forward to a...
Past ASCO President, John Ridgway Durant, MD, Dies at 82
John Ridgway Durant, MD, ASCO’s 20th President, was born on July 29th, 1930, and died on October 28th, 2012. Dates that mark a person’s birth and passing are made all the more significant by how that person filled the days that link the two milestones. Dr. Durant will be remembered fondly as a man...
Promoting a More Balanced Approach to Cancer Prevention and Treatment
Margaret I. Cuomo, MD, is a board-certified radiologist who served for many years as an attending physician in diagnostic radiology at North Shore University Hospital, Manhasset, New York. Dr. Cuomo is the daughter of former New York Governor Mario Cuomo and sister to Governor Andrew Cuomo. She is...
MSKCC’s Decision Not to Purchase New Cancer Drug Sparks Editorial and Unprecedented Actions
“At Memorial Sloan-Kettering Cancer Center, we recently made a decision that should have been a no-brainer: we are not going to give a phenomenally expensive new cancer drug to our patients.” That was the opening sentence of a New York Times op-ed piece written by three physicians from Memorial...
Dr. Lewis C. Cantley to Lead New Cancer Center at Weill Cornell Medical College and NewYork-Presbyterian Hospital
Leading cancer researcher Lewis C. Cantley, PhD, has been named Director of the newly established Cancer Center at Weill Cornell Medical College and NewYork-Presbyterian Hospital. According to Weill Cornell Medical College’s new Dean, Laurie H. Glimcher, MD, and NewYork-Presbyterian Hospital’s CEO, ...
Oncology Meetings
January 2013 3rd International Conference on Medical, Biological and Pharmaceutical SciencesJanuary 4-5 • Bali, Indonesia For more information: www.psrcentre.org Breast-Gynecological International Cancer CongressJanuary 17-18 • Cairo, Egypt For more information: www.bgicc.eg.net/ Highlights of ASH® ...
The Language of Cancer
I am a member of ASCO and read with interest your piece entitled “The Language of Cancer” in the October 15, 2012, issue of The ASCO Post. By way of introduction, I am an attending physician specializing in urologic oncology at Loyola University Medical Center. My group recently published an...
Health-care Crisis Reconsidered
As an oncologist in private practice, I usually read with great interest the many articles in The ASCO Post on issues regarding the politics of oncology practice. These articles deal with the major topics of the day, ranging from the high cost of oncologic care to shortages of generic drugs, to...
Updates on Ruxolitinib from ASCO and ASH 2012, including Long-term Survival Data
Ruxolitinib (Jakafi), a novel, oral JAK1 and JAK2 inhibitor, was approved by the FDA on November 16, 2011 for patients with intermediate- or high-risk myelofibrosis. The approval was based on its efficacy in reducing spleen size and improving disease-related burdensome symptoms. In the brief In the ...
American Cancer Society Honors Waun Ki Hong, MD, for Outstanding Clinical Research
Distinguished physician, scientist, mentor, and leader Waun Ki Hong, MD, recently accepted the American Cancer Society 2012 Medal of Honor Award in recognition of his novel, high-impact clinical research that has extended the frontiers of cancer treatment and prevention. Dr. Hong is Vice Provost...
American Society of Hematology Launches ASH Foundation
The American Society of Hematology (ASH) has announced the creation of the ASH Foundation dedicated to curing blood diseases. The new foundation will complement and build on the work of the Society by harnessing the generosity of donors to expand the reach of successful ASH programs and develop new ...
Karen E. Knudsen, PhD, Named New Editor-in-Chief of AACR Journal Molecular Cancer Research
The American Association for Cancer Research (AACR) recently announced that Karen E. Knudsen, PhD, Professor and Hilary Koprowski Chair in the Departments of Cancer Biology, Urology, and Radiation Oncology at Thomas Jefferson University in Philadelphia, and Deputy Director for Basic Science of the...
Top 10 Most Viewed Articles on ASCOPost.com for 2012
Novel Multikinase Inhibitor Improves Survival in Metastatic Colorectal CancerBy Caroline HelwickThe novel tyrosine kinase inhibitor regorafenib, given as a single agent to patients with treatment-refractory metastatic colorectal cancer, significantly improved overall survival and delayed disease...
ASCO Calls on Congress to Avoid Looming ‘Fiscal Cliff’
As Congress reconvenes for its lame duck session, ASCO calls on lawmakers to prevent devastating budget cuts to cancer care, research, and the drug review process citing the negative impact to millions of individuals who have cancer. The mandated cuts, known as “sequestration” under the Budget...
2012 In Review: Oncology Drugs/Indications Newly Approved by FDA
At press time, the FDA had granted approval for the following new agents and indications for cancer treatment in 2012. Cabozantinib (Cometriq) for the treatment of progressive metastatic medullary thyroid cancer. Cabozantinib is a small molecule that inhibits the activity of multiple tyrosine...
IMA901 Granted Orphan Drug Designation by FDA
immatics biotechnologies GmbH announced that the cancer vaccine IMA901 has been granted orphan drug designation from the FDA for the treatment of renal cell carcinoma (RCC) in HLA-A*02 positive patients. The FDA grants orphan drug designation to novel drugs aimed at treating rare diseases or...
Supplemental New Drug Application Submitted for Erlotinib as a First-line Therapy in Genetically Distinct NSCLC
Astellas Pharma US, Inc, announced it has submitted a supplemental New Drug Application (sNDA) to the FDA seeking approval for erlotinib (Tarceva) tablets for first-line treatment of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) whose tumors have epidermal growth...
Surefire Medical Receives FDA Clearance for Angiographic Catheters
Surefire Medical, Inc, announced that the company has received 510(k) FDA clearance to market its line of Surefire Angiographic Catheters. Surefire Medical will launch these products in the United States later this year. Surefire’s Angiographic Catheter line is designed to provide interventional...
FDA Grants Fast Track Designation to Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer
Nektar Therapeutics announced that the FDA has designated etirinotecan pegol (NKTR-102) as a Fast Track development program for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with an anthracycline, a taxane, and capecitabine (ATC)....
Molecular Breast Imaging an Option for Early Detection in High-risk Women
Molecular breast imaging, also known as breast-specific gamma imaging, was a key topic of discussion at the Radiological Society of North America (RSNA) Annual Meeting, held recently in Chicago. Molecular breast imaging can detect breast cancer missed by mammography, according to clinical data...
How Sequestration May Affect Cancer Research
Senator Sherrod Brown (D-Ohio) began his political career in 1974 as a state representative in Ohio. He served as Ohio’s Secretary of State between 1983 and 1991, went on to serve in the U.S. Congress from 1993 to 2006, and was elected to the Senate in 2006. A supporter of biomedical and cancer...
Fox Chase Researchers Find Most Medicare Patients Wait Weeks before Breast Cancer Surgery
Although patients may feel anxious waiting weeks from the time of their first doctor visit to evaluate their breast until they have breast cancer surgery, new findings from Fox Chase Cancer Center in Philadelphia show that these waits are typical in the United States. Results were published...
Richard R. Barakat, MD, Elected 2014 President of Two Gynecologic Oncology Medical Societies
Richard R. Barakat, MD, was recently named President-elect of the Society of Gynecologic Oncology (SGO) and the International Gynecologic Cancer Society (IGCS). He will serve as President of both societies beginning in 2014. Dr. Barakat is Vice Chair, Clinical Activities, Department of Surgery;...
Surgical Resection for Colorectal Cancer Liver Metastases: Who, When, How?
Many patients with colorectal liver metastases can undergo surgical resection with curative intent. Who are these patients and how are they best managed? In an interview with The ASCO Post, Steven A. Curley, MD, Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center,...
Bevacizumab Added to Radiation and Chemotherapy Improved Progression-free Survival in Newly Diagnosed Glioblastoma
Recently announced results of the phase III AVAglio study showed that bevacizumab (Avastin) in combination with radiation and temozolomide chemotherapy increased progression-free survival (a co-primary endpoint) by 36% compared to radiation and temozolomide chemotherapy plus placebo (hazard ratio...
ASTRO Names Neurosurgeon Mark P. Carol, MD, 2012 Honorary Member
The American Society for Radiation Oncology (ASTRO) has named Mark P. Carol, MD, a distinguished leader in the fields of intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT), as its 2012 Honorary Member. The title of Honorary Member is the highest honor ASTRO...
Current Perspectives on Triple-negative Breast Cancers
Triple-negative breast cancer—which lacks expression of the estrogen receptor, progesterone receptor, and HER2 oncogene—is a challenge for oncologists. The emergence of data showing strong heterogeneity for this subtype of breast cancer creates even more confusion regarding prognosis and...
Cabozantinib Approved for Treatment of Progressive Metastatic Medullary Thyroid Cancer
The FDA recently approved cabozantinib (Cometriq), for the treatment of patients with progressive metastatic medullary thyroid cancer. Cabozantinib is a small molecule that inhibits the activity of multiple tyrosine kinases, including RET, MET, and VEGF receptor 2. The approval was based on the...
Patients Treated for Colon Cancer Can Reduce Risk of Recurrence with Balanced Diet and Lower Carbohydrate Intake
In the News focuses on media reports that your patients may have questions about at their next visit. This continuing column will provide summaries of articles in the popular press that may prompt such questions, as well as comments from colleagues in the field. Patients who have received standard...
ASCO CEO Discusses the Society’s Initiatives
Created in 1964,a the American Society of Clinical Oncology (ASCO) has become the world’s preeminent professional cancer organization, with more than 30,000 members in the United States and abroad, unified by its founders’ “common concern for the patient with cancer.” The ASCO Post recently spoke...
Oncology Meetings
January 2013 Breast-Gynecological International Cancer CongressJanuary 17-18 • Cairo, EgyptFor more information: www.bgicc.eg.net/ Highlights of ASH® San Diego, CA and Toronto, CanadaJanuary 18-19 • San Diego, CA and Toronto, Ontario, CanadaFor more information: www.hematology.org/meetings...
Six Presidential Appointees Named to National Cancer Advisory Board
President Barack Obama recently announced his intent to nominate the following individuals to the National Cancer Advisory Board: David Christiani, MD; Judy E. Garber, MD; Liz Jaffee, MD; Beth Karlan, MD; Mack Roach III, MD; and Charles Sawyers, MD. David Christiani, MS, MD, MPH, is the Elkan Blout ...
The Rise of the Vintage Readers Book Club
Providing care beyond medical treatment, the multidisciplinary field of psychosocial oncology addresses the psychological, social, and emotional health of the patient with cancer. On an occasional basis, The ASCO Post will explore the realm of psychosocial oncology with a column guest edited by...
New Appointments at Cancer Centers Nationwide
Two new physicians have joined a growing team of cancer experts at Carolinas HealthCare System’s Levine Cancer Institute in Charlotte, North Carolina. Joshua S. Hill, MD, surgical oncologist, joins Levine Cancer Institute after completing a fellowship in surgical oncology at The University of Texas ...
President Obama Signs High-mortality Cancer Bill into Law
Just hours before the end of the 112th Congress, constitutional deadline for approval of a bill passed by that Congress, President Barack Obama signed into law the first legislation requiring comprehensive plans of research action for high-mortality cancers, with lung and pancreatic cancers given...
Never a Dull Moment: A Day in the Life of an Oncology Fellow
Oncology fellows represent the future of cancer care, bringing the best and brightest young doctors into a rigorous training environment that molds their future career paths. Due to an impending workforce shortage in cancer care, the public health-care demands placed on today’s oncology fellows...
Richard I. Fisher, MD, to Join Fox Chase Cancer Center and Temple University School of Medicine
On March 1, 2013, leading cancer center administrator and nationally recognized hematology/oncology expert Richard I. Fisher, MD, will assume leadership roles at Fox Chase Cancer Center, a member of the Temple University Health System, and Temple University School of Medicine, Philadelphia....
Online Prostate Cancer Information Is Written at Reading Levels above Many Americans’ Literacy Skills
Although 61% of Americans are going online to access health information,1 many of them may not understand what they find there, including information about prostate cancer treatment options. According to a new study published in The Journal of Urology,2 as many as 90 million Americans have literacy ...
FDA Expands Abiraterone’s Use for Late-stage Prostate Cancer
In December, the FDA approved an expanded indication for abiraterone acetate (Zytiga) in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. Trial Design The approval was based on a trial randomly assigning patients with metastatic...
Elekta Receives FDA 510(k) Clearance for Clarity 4D Monitoring
Elekta has received 510(k) clearance from the FDA for its Clarity 4D Monitoring software, enabling U.S. medical centers to implement a new way of reducing the uncertainty caused by prostate motion during radiation treatment. Physicians will be able to monitor the motion of the prostate and...
New Drug Application Submitted for Radium-223 for the Treatment of Castration-resistant Prostate Cancer with Bone Metastases
Bayer HealthCare announced that the company has submitted a New Drug Application to the FDA seeking approval for radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of patients with castration-resistant prostate cancer with bone metastases. “If approved, radium-223...
Peter P. Yu, MD, Elected ASCO President, 2014–2015, Others Named to ASCO Board
Peter P. Yu, MD, has been elected President of ASCO for a 1-year term beginning in June 2014. He will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2013. Additionally, three new members were elected to the ASCO Board of Directors, and three new members were...
Expert Point of View: Agnes Y. Lee, MD
Press conferencemoderator Agnes Y. Lee, MD, Medical Director of the Thrombosis Program and Associate Professor of Medicine at the University of British Columbia and Vancouver Coastal Health in Canada, said that apixaban is the third in a new line of anticoagulants for long-term prevention of...
Expert Point of View: Antonio Palumbo, MD
Antonio Palumbo, MD, Chief of the Myeloma Unit at the University of Torino in Italy, told The ASCO Post that the results with MLN9708 “look quite interesting,” and the drug could change the treatment of the disease. “This combination, with lenalidomide, accelerates response, and the ability to...
FDA Approves Ponatinib to Treat CML and Philadelphia Chromosome–positive ALL
In December, the FDA granted accelerated approval to ponatinib (Iclusig) for the treatment of adult patients with chronic-, accelerated-, or blast-phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome–positive...
National Comprehensive Cancer Network Appoints New CEO
The National Comprehensive Cancer Network (NCCN) recently appointed nationally regarded breast cancer expert Robert W. Carlson, MD, as its new CEO. Previously, Dr. Carlson was Professor of Medicine in the Division of Oncology and Medical Informatics, Stanford University Medical Center; he first...
Last-minute ‘Fiscal Cliff’ Deal by Congress Again Averts Medicare Cuts to Physicians
A last-minute patch to the sustainable growth rate formula included in the “fiscal cliff” deal averted massive cuts to oncologists who care for and treat Medicare patients. “This end-of-year crisis management once again demonstrates the critical need for fundamental reform of the Medicare...
More Thoughts on Rationing Cancer Care
I read the article about “The Ethics of Rationing Cancer Care” with interest (The ASCO Post, Dec 15, 2012). The issue of rationing (or rational) care has likely been debated since Hippocrates. Yet the topic has become a focus of acute interest with the current fiscal crises facing countries around...
